Navigation Links
ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
Date:9/27/2010

scores were recorded prior to the first treatment with REMURA and were compared to scores at Day 14, Day 42 and Day 52.

Authors of the posters were Simon P. Chandler, Ph.D., James A. Gow, M.D. and Timothy R. McNamara, Pharm.D. of ISTA Pharmaceuticals, Inc., Irvine, CA, USA; Sheri L. Rowen, M.D., of the Mercy Medical Eye and Cosmetic Surgery Center, Baltimore, MD, USA; and Neal A. Sher, M.D., F.A.C.S., Partner, Eye Care Associates, Minneapolis, MN, USA.

ISTA recently announced the Company has initiated its REMURA Phase 3 clinical study program.  Two Phase 3 studies to evaluate the efficacy and safety of REMURA are being conducted under a Special Protocol Assessment (SPA) agreed upon with the U.S. Food and Drug Administration (FDA), and two remaining Phase 3 safety studies are the subject of additional SPAs currently under review by the FDA.  ISTA anticipates starting the remaining safety studies later this year and reporting results for the first two Phase 3 efficacy and safety studies in the middle of 2011.

ABOUT DRY EYE DISEASE

Dry eye occurs when there is an imbalance of tears that provides moisture and lubrication to the eye, which can result in pain, itching, redness, blurry vision, light sensitivity and/or a gritty sensation or feeling of sand in the eye.  Causes for dry eye include environmental conditions such as air conditioning, smoke and dust, aging and menopause, side-effects from antihistamines and birth control pills, Sjogren's syndrome, rheumatoid arthritis and structural problems with the eye lid's ability to close. Left untreated, dry eye can lead to abrasions on the surface of the eye and damage to the cornea. Current treatments include artificial tears and ointments, topical steroids, a topical immunomodulator that is the only approved prescription eye drop treatment, and punctal occlusion (closing or plugging of tear drains).  

ABOUT REMURA AND BROMFENAC OPHTHALMIC SOLUTION'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
2. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
3. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
7. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
8. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... circuits are based on electrons, but one of the ... circuits, i.e. circuits based on light (photons) instead of ... create a stream of single photons and control their ... of attempts to achieve this control, but now scientists ... a steady stream of photons emitted one at a ...
(Date:8/29/2014)... 29, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or ... financial results for the six months ended June ... in Canadian dollars and presented under International Financial ... Highlights , Announced top-line results related ... endpoint for subjects enrolled in the Phase 2 ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 A major ... the biotech start-up dense realm of Boston-Cambridge, is gaining ... able investors. James Sherley, the Director of Boston’s Adult ... the local and national visibility of his company an ... 2013. , In addition to a social media marketing ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., the first ... hand sanitizer, asks food processors and food handling professionals ... sanitizer they’re currently using to Best Sanitizers’ Alpet® ... critical to fighting cross-contamination and the spread of pathogens ... there are key criteria that make a hand sanitizer ...
Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3
... and the University of California, Los Angeles (UCLA) have concluded ... chemistry for the rapid and robust labeling of proteins, peptides ... Emission Tomography (PET). "We are pleased ... cutting-edge work being developed by the Crump Institute," said Dr. ...
... Geim, a recipient of the 2010 Nobel Prize for graphene, ... electrons can magnetise graphene. The results, reported in ... the field of spintronics. Spintronics is a group of ... in addition to its fundamental electric charge that is exploited ...
... April 15, 2011 Carmell Therapeutics, a company that ... of injured tissues, has closed on a Series A ... facility and collect data for early clinical validation for ... was led by Harbor Light Capital Partners, a private ...
Cached Biology Technology:ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology 2New spin on graphene 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 2Carmell Therapeutics Completes Series A Financing to Advance the Development of Novel Bioactive Plastics 3
(Date:8/31/2014)... A fast-sensitive "electronic-nose" for sniffing the highly infectious bacteria ... stomach cramps, has been developed by a team at ... the research team has demonstrated that it is possible ... which would lead to rapid diagnosis of the ... could be possible to identify different strains of the ...
(Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
(Date:8/29/2014)... from the University of Texas Medical Branch at Galveston has ... antibodies can completely protect monkeys against a lethal dose of ... time when the disease is severe. , Thomas Geisbert, professor ... Nature discussing advances in Ebola treatment research. The filoviruses ... most deadly of pathogens, with fatality rates of up to ...
Breaking Biology News(10 mins):Scientists develop 'electronic nose' for rapid detection of C. diff infection 2A new way to diagnose malaria 2A new way to diagnose malaria 3Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2
... , April 30, 2013 /PRNewswire-iReach/ -- Clinilabs, an early phase ... industry, today announced the arrival of Dr. Admir ... provide expertise in the development of drugs to treat pain, ... clinical trials. Dr. Admir Hadzic ...
... integrates three large sets of genomic data available through ... that might predict survival in patients with the most ... researchers at the Ohio State University Comprehensive Cancer Center ... Solove Research Institute (OSUCCC James) initially analyzed messenger ...
... whales sing complex songs in tropical waters during the ... latitudes at other times of the year. NOAA ... whale movements to acoustic behavior on a feeding ground ... published April 10 in the journal PLOS ONE ...
Cached Biology News:Clinilabs Welcomes Anesthesiologist Dr. Admir Hadzic Who Will Provide CSF/cCSF Capabilities For Clinilabs 2Big data analysis identifies prognostic RNA markers in a common form of breast cancer 2Researchers track singing humpback whales on a Northwest Atlantic feeding ground 2
... is used to perform runs with ... the Experion automated electrophoresis system. The ... simulated gel views and summarizes size, ... Results table. This software is for ...
... Top cover cold rolled steel with stove ... surface polyethylene Front, ... 3 UV lamps Internal ... interlocked with fluorescent light Lighting ...
...
... this set of Antibody Microarray slides ... a total of over 2100 spots,including ... control. Antibodies belonging to many important ... cycle progression, signal transduction and gene ...
Biology Products: